Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

MSKCC Stage I NSGCT Nomogram

This tool uses the MSKCC criteria (Lymphovascular Invasion and Predominance of Embryonal Carcinoma) to predict the risk of occult nodal metastases in Clinical Stage I Non-Seminomatous Germ Cell Tumor (NSGCT).

Evidence-based context for fast calculator use

Purpose:
MSKCC NSGCT Nomogram predicts occult retroperitoneal metastasis risk in clinical stage I non-seminoma to guide surveillance versus RPLND decisions.
Population:
patients with germ-cell tumors in the metastatic, relapse, or pathology setting described by the model
Factors:
Lymphovascular Invasion, Percentage of Embryonal Carcinoma
Reference:
Steyerberg EW, Habbema JD, Keizer HJ, et al. Prediction of occult retroperitoneal metastases in clinical stage I nonseminoma: construction and validation of a model based on six studies. J Clin Oncol. 2006;24(26):4236-4242.
HomeMSKCC Stage I NSGCT Nomogram
Pin your most used calculators here by clicking the star in the dropdown.

MSKCC Stage I NSGCT Nomogram

%

Clinical Context & Background

This tool uses the MSKCC criteria (Lymphovascular Invasion and Predominance of Embryonal Carcinoma) to predict the risk of occult nodal metastases in Clinical Stage I Non-Seminomatous Germ Cell Tumor (NSGCT). It helps decide between Active Surveillance vs. RPLND or Adjuvant Chemotherapy.
Primary Source EvidenceSteyerberg EW, Habbema JD, Keizer HJ, et al. Prediction of occult retroperitoneal metastases in clinical stage I nonseminoma: construction and validation of a model based on six studies. J Clin Oncol. 2006;24(26):4236-4242.
Formula Logic
Risk based on LVI status and % Embryonal Carcinoma.

Reference Data

LVIEmbryonal %Occult Metastasis Risk
NegativeLower %Low (~10-15%)
PositiveHigher %High (~50%)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use MSKCC Stage I NSGCT Nomogram when mSKCC NSGCT Nomogram predicts occult retroperitoneal metastasis risk in clinical stage I non-seminoma to guide surveillance versus RPLND decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Negative through Positive.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm histology, primary site, stage, marker timing, metastatic sites, treatment line, fertility needs, and specialist guideline.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • First-line metastatic, stage I, and post-chemotherapy models answer different questions.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with germ-cell tumors in the metastatic, relapse, or pathology setting described by the model

How to apply this result

For a representative case, verify Lymphovascular Invasion, Percentage of Embryonal Carcinoma, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Related Tools

IGCCCG Risk Classification (2021 Update)

Frequently Asked Questions

When should MSKCC Stage I NSGCT Nomogram be used?

Use it for patients with germ-cell tumors in the metastatic, relapse, or pathology setting described by the model when all required inputs and the intended clinical setting are confirmed.

Can MSKCC Stage I NSGCT Nomogram determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.